Dabrafenib in the treatment of advanced melanoma

Drugs of Today

Volumn 49, Issue 6, 2013, Pages 377-385

  Medina, T ^a   Amaria, R N ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

BRAF; Dabrafenib; Melanoma; Targeted therapy

Indexed keywords

B RAF KINASE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; DABRAFENIB; DACARBAZINE; MULTIDRUG RESISTANCE PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRAMETINIB; VEMURAFENIB;

ACTINIC KERATOSIS; ADVANCED CANCER; ALOPECIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL GROWTH; CENTRAL NERVOUS SYSTEM METASTASIS; CHILL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HYPERKERATOSIS; HYPOTENSION; KERATOACANTHOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PAPILLOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROTO ONCOGENE; SEBORRHEIC KERATOSIS; SEPSIS; SKIN CARCINOMA; SKIN PAPILLOMA; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; UPREGULATION; VOMITING; WEAKNESS;

BRAF; DABRAFENIB; MELANOMA; TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; MELANOMA; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84879999533     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.6.1968669     Document Type: Article

References (23)

1. Jemal, A., Saraiya, M., Patel, P. et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. 2011, 65(5 Suppl 1): S17-25 e1-3.
2. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. 2002, 417(6892): 949-54.
3. Tsai, J., Lee, J.T., Wang, W. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. 2008, 105(8): 3041-6.
4. Long, G.V., Menzies, A.M., Nagrial, A.M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. 2011, 29(10): 1239-46.
5. Bauer, J., Buttner, P., Murali, R. et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. 2011, 24(2): 345-51.
6. Falchook, G.S., Long, G.V., Kurzrock, R. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. 2012, 379(9829): 1893-901.
7. Long, G.V., Trefzer, U., Davies, M.A. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. 2012, 13(11): 1087-95.
8. Chapman, P.B., Hauschild, A., Robert, C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. 2011, 364(26): 2507-16.
9. Hauschild, A., Grob, J.J., Demidov, L.V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. 2012, 380(9839): 358-65.
10. Sosman, J.A., Kim, K.B., Schuchter, L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. 2012, 366(8): 707-14.
11. Flaherty, K.T., Infante, J.R., Daud, A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. 2012, 367(18): 1694-703.
12. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., Tuveson, D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. 2003, 63(17): 5198-202.
13. Gentilcore, G., Madonna, G., Mozzillo, N., Ribas, A., Cossu, A., Palmieri, G., Ascierto, P.A. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. 2013, 13: 17.
14. The study to determine safety, tolerability and pharmacokinetics of oral dabrafenib in pediatric subjects (NCT01677741). ClinicalTrials.gov Web site, Accessed June 10, 2013.
15. Chapman, P.B., Hauschild, A., Robert, C., et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV660E-mutated melanoma. 48th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2012, Abst 8502.
16. Carlino, M.S., Fogarty, G.B., Long, G.V. Treatment of melanoma brain metastases: a new paradigm. 2012, 18(2): 208-12.
17. A phase 2 prospective trial of dabrafenib with stereotactic radiosurgery in BRAFV600E melanoma brain metastases (NCT01721603). ClinicalTrials.gov Web site, Accessed June 10, 2013.
18. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 2010, 468(7326): 968-72.
19. Nazarian, R., Shi, H., Wang, Q. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 2010, 468(7326): 973-7.
20. Dabrafenib plus trametinib vs vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma (COMBI-v) (NCT01597908). ClinicalTrials.gov Web site, Accessed June 10, 2013.
21. A study comparing trametinib and dabrafenib combination therapy to dabrafenib monotherapy in subjects with BRAF-mutant melanoma (NCT01584648). ClinicalTrials.gov Web site, Accessed June 10, 2013.
22. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. 2010, 363(9): 809-19.
23. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar(R) (dabrafenib) capsules and the first MEK-inhibitor Mekinist(TM) (trametinib) tablets, approved by FDA as single-agent therapies [news release]. GlaxoSmithKline plc, May 29, 2013. Accessed June 10, 2013.